Antithrombin gamma - Kyowa Hakko Kirin

Drug Profile

Antithrombin gamma - Kyowa Hakko Kirin

Alternative Names: Acoalan; KW-3357

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Hakko Kirin
  • Class Alpha globulins; Anticoagulants; Antithrombins; Antithrombotics; Immunoglobulins; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Antithrombin III deficiency; Disseminated intravascular coagulation

Most Recent Events

  • 28 Sep 2016 Kyowa Hakko Kirin files sNDA for approval of additional 1800IU vial formulation for Antithrombin III deficiency in Japan
  • 03 Jul 2015 Registered for Antithrombin III deficiency in Japan (IV)
  • 03 Jul 2015 Registered for Disseminated intravascular coagulation in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top